A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer — StellaPhase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(2 sites)
China
Fujian Cancer Hospital, Fuzhou, Fujian Shandong University Qilu Hospital, Jinan, Shandong Last updated November 2025